Table 2.
Tumor Type | All Patients | TERT Wild Type | TERT Mutated | P Value |
---|---|---|---|---|
DTCs (n = 402) | ||||
Clinicopathological | ||||
Age at diagnosis, y (n = 402) | 46.0 ± 16.0 | 44.5 ± 15.6 | 60.2 ± 12.7 | <.001 |
Gender (n = 395) | ||||
Female | 304 (77.0) | 278 (77.7) | 26 (70.3) | NS (.31) |
Male | 91 (23.0) | 80 (22.3) | 11 (29.7) | |
Mean tumor size, cm (n = 376) | 2.7 ± 1.9 | 2.6 ± 1.8 | 3.6 ± 2.3 | .002 |
Extrathyroidal extension (n = 317)a | ||||
Present | 184 (58.0) | 167 (57.4) | 17 (65.4) | NS (.43) |
Vascular invasion (n = 310)b | ||||
Present | 142 (45.8) | 129 (45.4) | 13 (50.0) | NS (.65) |
LN metastases (n = 345) | ||||
Present | 210 (60.9) | 189 (61.0) | 21 (60.0) | NS (.91) |
Distant metastases (n = 294) | ||||
Present | 44 (15.0) | 34 (12.5) | 10 (43.5) | <.001 |
Stage (n = 254) | ||||
I | 132 (52.0) | 129 (55.1) | 3 (15.0) | <.001 |
II | 33 (13.0) | 31 (13.3) | 2 (10.0) | |
III | 41 (16.1) | 37 (15.8) | 4 (20.0) | |
IV | 48 (18.9) | 37 (15.8) | 11 (55.0) | |
Other genetic alterations | ||||
BRAF mutation (n = 357) | 148 (41.5) | 130 (40.2) | 18 (52.9) | NS (.15) |
NRAS mutation (n = 365) | 29 (7.9) | 24 (7.3) | 5 (14.3) | NS (.15) |
PTCs (n = 332) | ||||
Clinicopathological | ||||
Age at diagnosis, y (n = 332) | 44.8 ± 15.6 | 43.6 ± 15.3 | 58.4 ± 13.2 | <.001 |
Gender (n = 327) | ||||
Female | 254 (77.7) | 237 (78.5) | 17 (68.0) | NS (.23) |
Male | 73 (22.3) | 65 (21.5) | 8 (32.0) | |
Mean tumor size, cm (n = 315) | 2.4 ± 1.5 | 2.3 ± 1.4 | 3.2 ± 2.2 | .005 |
Extrathyroidal extension (n = 268)a | ||||
Present | 176 (65.7) | 162 (64.8) | 14 (77.8) | NS (.26) |
Vascular invasion (n = 257)b | ||||
Present | 103 (40.1) | 98 (40.7) | 5 (31.3) | NS (.46) |
LN metastases (n = 298) | ||||
Present | 202 (67.8) | 184 (66.9) | 18 (78.3) | NS (.26) |
Distant metastases (n = 263) | ||||
Present | 36 (13.7) | 31 (14.7) | 5 (27.8) | NS (.07) |
Stage (n = 225) | ||||
I | 124 (55.1) | 121 (57.3) | 3 (21.4) | .02 |
II | 25 (11.1) | 24 (11.4) | 1 (7.1) | |
III | 36 (16.0) | 32 (15.2) | 4 (28.6) | |
IV | 40 (17.8) | 34 (16.1) | 6 (42.9) | |
Other genetic alterations | ||||
BRAF mutation (n = 301) | 148 (49.2) | 130 (46.9) | 18 (75.0) | .008 |
NRAS mutation (n = 301) | 15 (5.0) | 14 (5.1) | 1 (4.2) | NS (.85) |
FTCs (n = 70) | ||||
Clinicopathological | ||||
Age at diagnosis, y (n = 70) | 51.8 ± 16.4 | 49.3 ± 16.3 | 63.8 ± 11.0 | .004 |
Gender (n = 68) | ||||
Female | 50 (73.5) | 41 (73.2) | 9 (75.0) | NS (.90) |
Male | 18 (26.5) | 15 (26.8) | 3 (25.0) | |
Mean tumor size, cm (n = 61) | 4.4 ± 2.6 | 4.4 ± 2.6 | 4.4 ± 2.5 | NS (.96) |
Extrathyroidal extension (n = 49)a | ||||
Present | 8 (16.3) | 5 (12.2) | 3 (37.5) | NS (.08) |
Vascular invasion (n = 53)b | ||||
Present | 39 (73.6) | 31 (72.1) | 8 (80.0) | NS (.61) |
LN metastases (n = 47) | ||||
Present | 8 (17.0) | 5 (14.3) | 3 (25.0) | NS (.39) |
Distant metastases (n = 31) | ||||
Present | 8 (25.8) | 3 (11.5) | 5 (100.0) | <.001 |
Stage (n = 29) | ||||
I | 8 (27.6) | 8 (34.8) | 0 | .007 |
II | 8 (27.6) | 7 (30.4) | 1 (16.7) | |
III | 5 (17.2) | 5 (21.7) | 0 | |
IV | 8 (27.6) | 3 (13.1) | 5 (83.3) | |
Other genetic alterations | ||||
BRAF mutation (n = 56) | 0 | 0 | 0 | c |
NRAS mutation (n = 64) | 14 (21.9) | 10 (18.9) | 4 (36.4) | NS (0.20) |
Undifferentiated thyroid carcinomas (poorly differentiated + anaplastic) (n = 67) | ||||
Clinicopathological | ||||
Age at diagnosis, y (n = 67) | 61.5 ± 16.2 | 58.3 ± 17.6 | 68.7 ± 9.6 | .003 |
Gender (n = 64) | ||||
Female | 38 (59.4) | 22 (50.0) | 16 (80.0) | .02 |
Male | 26 (40.6) | 22 (50.0) | 4 (20.0) | |
Mean tumor size, cm (n = 42) | 6.5 ± 3.2 | 6.3 ± 3.4 | 6.8 ± 2.9 | NS (.62) |
Extrathyroidal extension (n = 56)a | ||||
Present | 47 (83.9) | 32 (82.1) | 15 (88.2) | NS (.56) |
Vascular invasion (n = 15)b | ||||
Present | 15 (100.0) | 11 (100.0) | 4 (100.0) | c |
LN metastases (n = 46) | ||||
Present | 24 (52.2) | 16 (57.1) | 8 (44.4) | NS (.40) |
Distant metastases (n = 43) | ||||
Present | 32 (74.4) | 19 (70.4) | 13 (81.3) | NS (.43) |
Stage (n = 56) | ||||
I | 2 (3.6) | 2 (5.3) | 0 | NS (.39) |
II | 3 (5.4) | 3 (7.9) | 0 | |
III | 4 (7.1) | 2 (5.3) | 2 (11.1) | |
IV | 47 (83.9) | 31 (81.5) | 16 (88.9) | |
Other genetic alterations | ||||
BRAF mutation (n = 65) | 10 (15.4) | 6 (13.6) | 4 (19.0) | NS (0.57) |
NRAS mutation (n = 61) | 17 (27.9) | 9 (22.5) | 8 (38.1) | NS (0.20) |
Abbreviations: LN, lymph node; n, number of patients with available data for each feature; NS, not significant. Numbers in parentheses represent percentages within each category. Bold values indicate the result was statistically significant.
Extrathyroidal extension was defined as having disease extending beyond the thyroid capsule, including either microscopic or macroscopic invasion.
Vascular invasion was defined as the presence of intravascular tumor cells either covered by endothelium or associated with thrombus, affecting lymphatic or blood vessels within or beyond the tumor capsule.
No statistics were computed due to constant numbers of one feature.